98%
921
2 minutes
20
HIV-associated multicentric Castleman disease (HIV-MCD) is a rare, life-threatening lymphoproliferative disorder featuring systemic inflammation and marked lymphadenopathy. HIV-MCD is characterized by a human herpesvirus-8 (HHV-8) infection, with an increasing incidence despite advances in antiretroviral therapy (ART). Although HHV-8 viremia is a recognized indicator of disease recurrence, the necessity of intervention for low-level viremia reactivation remains unclear. We present a case of a man with HHV-8-associated HIV-MCD and Kaposi sarcoma (KS) who achieved a prolonged remission despite occasional episodes of low-level viremia. A 58-year-old man with untreated HIV infection presented with fever, night sweats, and fatigue. Histopathological analysis confirmed the diagnosis of HIV-MCD with KS. He received rituximab, liposomal doxorubicin, and ART which induced remission. The patient was followed for 120 weeks with serial monitoring of HHV-8 DNA levels. Although occasional viremia was observed, no relapse occurred. When mild HHV-8 reactivation occurred post-therapy without clinical relapse, we avoided unnecessary treatments with potential drug-related toxicities. No established prevention for MCD flares exists, and prolonged rituximab or valganciclovir use risks pulmonary and hematologic toxicity. Thus, HHV-8 DNA monitoring and selective interventions seem practical. Timely diagnosis and immunochemotherapy, including rituximab and liposomal doxorubicin, are critical for the management of HIV-MCD with concurrent KS. This combination mitigated KS progression. Successful management of HIV-MCD requires early recognition and administration of ART and targeted therapies, which can result in sustained remission. Close HHV-8 DNA monitoring and clinical assessment minimize the need for additional treatment, underscoring the importance of balancing efficacy and safety in individualized HIV-MCD management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jiac.2025.102806 | DOI Listing |
J Med Virol
September 2025
Department of Endocrinology, University of Health Sciences Ankara Etlik City Hospital, Ankara, Türkiye.
Human herpesvirus 8 (HHV-8) positivity rates vary across regions. The rates are higher in immunosuppressed patients. There is a potential association between HHV-8 and type 2 diabetes.
View Article and Find Full Text PDFJ Infect Chemother
September 2025
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
HIV-associated multicentric Castleman disease (HIV-MCD) is a rare, life-threatening lymphoproliferative disorder featuring systemic inflammation and marked lymphadenopathy. HIV-MCD is characterized by a human herpesvirus-8 (HHV-8) infection, with an increasing incidence despite advances in antiretroviral therapy (ART). Although HHV-8 viremia is a recognized indicator of disease recurrence, the necessity of intervention for low-level viremia reactivation remains unclear.
View Article and Find Full Text PDFJ Vis Exp
August 2025
Program in Molecular and Cellular Oncogenesis, The Wistar Institute;
Kaposi's sarcoma-associated herpesvirus (KSHV), a gammaherpesvirus implicated in multiple human malignancies, can undergo lytic replication during primary infection, a process that contributes to viral dissemination, immune evasion, and disease pathogenesis. However, the lack of robust in vitro systems for de novo lytic infection has limited insights into early infection events. Here, we present a tractable protocol that employs human colorectal cancer HCT 116 cells as targets for infection with cell-free virions derived from KSHV bacterial artificial chromosome 16 (BAC16)-reactivated iSLK producer cells.
View Article and Find Full Text PDFVirology
August 2025
International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, 7925, South Africa; Division of Medical Biochemistry and Structural Biol
Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are oncogenic human γ-herpesviruses highly prevalent in Sub-Saharan Africa. Both establish latent early-life infections, with intermittent lytic reactivations, often triggered by viral co-infections, particularly in immunocompromised individuals. In this retrospective observational cross-sectional sub-study, we leveraged a cohort of 407 non-hospitalised people living with HIV (PLWH) attending antiretroviral therapy services in South Africa during the COVID-19 pandemic, with previously reported increased reactivation of KSHV upon SARS-CoV-2 exposure, particularly in COVID-19 unvaccinated individuals (Lambarey et al.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Department of Dermatology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Primary effusion lymphoma (PEL) is a rare B-cell lymphoma with an extremely poor prognosis that is associated with long-term persistent latent infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV). However, studies on the correlation between KSHV genotype and PEL development in elderly patients are still lacking. We present the first global case of non-HIV, non-effusive, difficult-to-diagnose PEL with disseminated Kaposi's sarcoma (KS) in an elderly patient of Bouyei nationality, dynamically demonstrating that KSHV and EBV co-infection promote tumorigenesis.
View Article and Find Full Text PDF